Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; likewise those that respond to prostaglandin analogsEpiscleral venous pressure changes did not show a trend vs. placeboSafety profile is consistent with that of the first Phase 3 trial, Mont BlancNCX 470 intraocular pressure lowering efficacy and safety have already been demonstrated in the Phase ...

Insmed (INSM) 2025 Conference May 13, 2025 05:20 PM ET Speaker0 Five Healthcare Conference in Las Vegas. My name is Jason Zemanski. I'm one of the SMID cap analysts here at the bank. Joining me on stage is my associate Cameron Bozdag, and I'm very pleased to be sharing the stage here with Will Lewis, chair and CEO of Insmed. Thank you for joining us. Thank you for having me. Absolutely. So a lot to talk about, but I think most investors right now are concentrated on a phase two asset of yours, TPIP. PAH dat ...

Summary of Liquidia's Conference Call Company Overview - **Company**: Liquidia - **Industry**: Biotech, specifically in the cardiopulmonary space - **Lead Product**: Eutrebia, a treatment for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PHILD) [3][12] Key Points and Arguments Product Development and Approval - Liquidia is approaching its PDUFA date for Eutrebia, which is set for May 24, indicating a potential approval for the treatment of PAH and PHILD [3][15] - Eutrebia utilizes proprietary print technology to create a dry powdered formulation of treprostinil, allowing for better lung deposition and tolerability [3][5] - The company has developed five launch strategies, including product profile development, a best-in-class sales force, patient support services, product availability, and payer access [4][5] Market Dynamics - The reference brand, United Therapeutics' Tyvaso, has a sales run rate of approximately $2 billion, with a market characterized by less than 20% penetration in PHILD [19][21] - Liquidia estimates the PHILD market to have around 60,000 patients, presenting significant growth opportunities [21][30] - The PAH market is described as crowded, with Liquidia aiming to position Eutrebia as the first choice among prostacyclins due to its ability to titrate to higher doses [22][23] Competitive Landscape - Liquidia is aware of ongoing litigation from United Therapeutics, which has filed multiple patents against them to delay Eutrebia's market entry [8][11] - The company is confident in its legal position and is committed to providing alternative treatments for patients [12][69] Sales and Marketing Strategy - Liquidia has a 50-person sales force with extensive experience in PAH, focusing on building relationships with healthcare providers [36][38] - The sales force has engaged in unbranded promotional efforts to educate physicians about the product and its technology [38][39] - The company plans to ensure broad access to Eutrebia through relationships with payers, targeting a market mix of approximately 50% Medicare Part D and 35-40% commercial [48][49] Product Differentiation - Eutrebia is designed to be easy to use, requiring no refrigeration and allowing for quick inhalation [51][55] - The device is familiar to pulmonologists, which may facilitate adoption among patients [55][56] - Liquidia emphasizes the importance of patient-reported outcomes and quality of life improvements as key measures of success [58][61] Future Outlook - Liquidia is preparing for a Phase 3 study of L606, a liposomal sustained release formulation, which could provide a once-daily treatment option [64][66] - The company is focused on maximizing the benefits of inhaled treprostinil and is optimistic about its long-term positioning in the market [66] Additional Important Information - Liquidia has been proactive in manufacturing commercial supply in anticipation of approval, ensuring sufficient product availability at launch [44][45] - The company is committed to addressing the needs of patients with PAH and PHILD, aiming to provide effective treatment options [12][69]

Nobody has a perfect track record when it comes to investing. But I feel like I have a pretty solid one. One company that I could point to as an example of this is Champion Homes (NYSE: SKY ), anCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live c ...

Core Viewpoint - Latin Metals Inc. has announced the appointment of Eduardo Leon as Vice President of Exploration and has upsized its private placement to raise gross proceeds of up to $1.3 million [1][4]. Company Developments - Eduardo Leon has been with Latin Metals since 2020 and has played a significant role in the company's exploration efforts in South America, particularly in identifying copper potential in northwest Argentina [2]. - Leon's promotion is attributed to his leadership and strategic thinking, aligning with the company's prospect generator model aimed at maximizing exploration upside while minimizing dilution [3]. - The company has upsized its non-brokered private placement due to strong investor interest, now targeting total gross proceeds of up to $1.3 million, consisting of up to 11,818,182 units priced at $0.11 each [4]. Financial Details - Each unit in the private placement includes one common share and one purchase warrant, allowing the holder to buy a share at $0.20 for 36 months [4]. - The proceeds from the financing will be allocated for exploration, generative work, and general working capital [5]. - The company may pay finder's fees of up to 7% of the total gross proceeds raised, along with finder's warrants [6]. Stock Options - Latin Metals has granted 750,000 stock options to certain consultants, allowing them to purchase shares at $0.12 each for 36 months, representing 8.6% of the issued and outstanding stock [9]. Upcoming Events - The company will participate in several industry conferences, providing opportunities to connect with investors and showcase its exploration progress in Argentina and Peru [10]. Company Overview - Latin Metals operates under a prospect generator model, focusing on copper, gold, and silver exploration in Peru and Argentina, with 18 projects and partnerships with major mining companies [11].

TRADING UPDATE Irish Continental Group plc ("ICG" or "the Group") issues this trading update which covers carryings for the year to date to 3 May 2025 and financial information for the first four months of 2025, i.e. 1 January to 30 April with comparisons against the corresponding period in 2024. All figures are unaudited. Volumes (Year to date, 3 May 2025) | | 2025 | 2024 | Change vs | | --- | --- | --- | --- | | | | | 2024 | | Cars | 140,800 | 151,500 | (7.1%) | | RoRo Freight | 259,400 | 260,900 | (0.6%) ...

Core Points - Senator Thom Tillis, a key Republican, announced he would not support Ed Martin's nomination as U.S. Attorney for the District of Columbia, significantly jeopardizing Martin's chances for Senate confirmation [1][2] - Tillis expressed concerns over Martin's support for defendants involved in the January 6, 2021, Capitol riot, which was incited by former President Trump [1][2] - The likelihood of Martin's nomination being reported out of the Senate Judiciary Committee is low, as Tillis's opposition could lead to a tie vote, which would prevent the nomination from advancing [2][3] Summary by Sections Nomination Status - Tillis's refusal to support Martin's nomination is seen as a potentially fatal blow to his confirmation prospects [1][2] - With Tillis as a "no" vote, the best possible outcome for Martin from the committee would be a tie vote of 11-11, which would not allow the nomination to proceed [3] Concerns Raised - Tillis highlighted that while Martin acknowledged some individuals were over-prosecuted, he believed that 200 to 300 individuals should not have received pardons [3] - Tillis stated that if Martin were nominated for any district other than the one where the January 6 events occurred, he would likely support him [4] Sentiments on January 6 - Tillis expressed a strong stance against those who entered the Capitol on January 6, indicating that they should face imprisonment, although he noted the duration of imprisonment could be debated [5]

Group 1 - The article emphasizes the importance of adapting opinions as market conditions change, highlighting that changes can occur gradually or rapidly [1] - Crude Value Insights provides an investment service focused on oil and natural gas, concentrating on cash flow and companies that generate it, which leads to potential value and growth opportunities [1] - Subscribers benefit from a comprehensive stock model account, detailed cash flow analyses of exploration and production (E&P) firms, and live discussions about the sector [2] Group 2 - A promotional offer is available for a two-week free trial, encouraging new users to explore opportunities in the oil and gas sector [3]

Core Points - Oroco Resource Corp. has filed and received a receipt for a final short form base shelf prospectus allowing the distribution of up to C$75,000,000 in various securities over a 25-month period [2][3] - The prospectus aims to provide the company with flexibility to capitalize on financing opportunities and favorable market conditions [3] - The company holds an 85.5% interest in the Core Concessions of the Santo Tomas Project, covering 1,173 hectares, and an 80% interest in an additional 7,861 hectares, totaling 9,034 hectares [6][7] - The Santo Tomas Project is located near infrastructure such as highways and rail, approximately 170 km from the Pacific deep-water port at Topolobampo [8]

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agentMELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in France by ANSM2 for the detection and localization of prostate-specific membrane antigen (PSMA)-positive le ...